Bristol-Myers Squibb Compnay

Medarex Inc.

Cytomx Therapeutics, Inc.

Sun Microsystems, Inc.

Corixa Corporation

E. R. Squibb Sons, Inc.

Shrikant Deshpande

Mohan Srinivasan

Guodong Chen

Richard Y Huang

Vangipuram S Rangan

Ginger Chao Rakestraw

Alan J Korman

Haichun Huang

Josephine M Cardarelli

Changyu Wang

David B Passmore

Karla Ann Henning

Christine Bee

Hans S Keirstead

Xiang Shao

Natalie Bezman

Amy D Jhatakia

Thomas E Lane

Michael T Liu

James William West

Steven Sheriff

Kimberly Ann Tipton

John P Throup

Qihong Zhao

John J Englehardt

Rose A Dibella

Cristian Rodriguez

Huadong Sun

Mark J Selby

Ekaterina G Deyanova

Chetana Rao-Naik

Maureen C Howard

Li-Sheng Lu

John J Engelhardt

Jun Zhang

Scott Michael Carter

Richard C Murphy

Mario G Ornelas

Walter Ferlin

Subhashini Arimilli

Ginger C Rakestraw

Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.

Activatable anti-CTLA-4 antibodies and uses thereof

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

IP-10 antibodies and their uses

Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies

An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.

Antibodies conjugatable by transglutaminase and conjugates made therefrom

A system and method for predicting whether a dynamic reconfiguration of a resource of a resource domain would be successful, prior to attempting the reconfiguration. A resource domain includes one or more computer resources (e.g., physical, logical and pseudo devices) and a graph management agent configured to maintain a graph representing the resources and dependencies between resources. Vertices of the graph represent resources; edges represent dependencies. A resource domain may also include a set of policies or constraints regarding resources and reconfigurations of resources. An illustrative constraint may specify that a particular resource (e.g., a multi-pathed logical device) must have a minimal number of paths (e.g., two). The graph agent identifies the effect the dynamic reconfiguration operation would have upon the resources and dependencies, and determines whether any constraints would be violated. If no constraints would be violated, the graph management agent may indicate that the reconfiguration would succeed.

System and method for dynamic resource configuration using a dependency graph

The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.

Chemokine receptor peptide for inducing an immune response

Growing community of inventors

Fremont, CA, United States of America

Shrikant Deshpande